Atlas Trials

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Clinical trial NCT02553317 · COMPLETED

Trial details

NCT number
NCT02553317
Sponsor
Ablynx, a Sanofi company
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Acquired Thrombotic Thrombocytopenic Purpura
Start date
2015-11-01
Primary completion
2017-08-01
Enrollment
145

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.